Fibrosis: From Basic Mechanisms to Targeted Therapies (Q3)

joint with the meeting on Stromal Cells in Immunity (Q4)

Scientific Organizers: Robert Lafyatis, Paolo G.V. Martini, Dean Sheppard and Lucie Peduto


February 7—11, 2016

Keystone Resort, Keystone, Colorado, USA


Sponsored by Bayer HealthCare Pharmaceuticals, Biogen, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Shire Human Genetic Therapies and Theravance Biopharma


BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.

Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.

** Meeting has ended **

Discounted Abstract Deadline: October 8, 2015

*All deadlines end at 11:59 PM US Mountain Standard Time

Abstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register

Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract early allows us to:
  • submit your abstract to organizers to be considered for a short talk
  • accept your abstract online
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
(The Abstract Deadline: is November 10, 2015)

Global Health Travel Award Deadline:

*All deadlines end at 11:59 PM US Mountain Standard Time


Global Health Travel Award Details: You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline and complete the other required steps (verify your contact information and submit a recommendation letter) to be considered for a travel award.


Click here to learn more about Global Health Travel Awards.

Scholarship Deadline: October 8, 2015

*All deadlines end at 11:59 PM US Mountain Standard Time


Scholarship Details: You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.

Click here to learn more about Scholarships.

Abstract Deadline: November 10, 2015

*All deadlines end at 11:59 PM US Mountain Standard Time


Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register

Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract by the Abstract Deadline allows us to:

  • submit your abstract to organizers to be considered for a short talk
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.

(Discounted Abstract Deadline: is October 8, 2015)

Discounted Registration Deadline: December 8, 2015

*All deadlines end at 11:59 PM US Mountain Standard Time


Registration Fee: 795.00 USD* (includes 150.00 USD discount)
Student Registration Fee: 570.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

After the Discounted Registration Deadline:


Registration Fee: 945.00 USD*
Student Registration Fee: 720.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

Registration spaces are limited and may fill prior to discounted registration deadline.

Please be advised that some meeting participants have received calls and emails from a number of different housing services, including "Exhibitors Housing Services," “Expo Housing Services,” "Global Housing," etc. THESE COMPANIES ARE NOT AFFILIATED WITH KEYSTONE SYMPOSIA and are not authorized by Keystone Symposia to contact you. These companies may tell you that the meeting is filling, without any actual knowledge to that effect, and pressure you into giving them your credit card number to make a lodging reservation with them.

We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.

Meeting Summary



Fibrosis is the primary process of many diseases and the end-stage of many more, frequently leading to organ failure. However, the mechanisms leading to fibrosis have been poorly understood and available therapeutics targeting fibrosis limited. Increasingly, fibrosis is understood as a dynamic process that is orchestrated by the immune system, or activated by inflammation or cellular stress. Fibrosis of lung, kidney, skin, liver and muscle typically follow a variety of different stimuli. Advances in understanding Th2 cell responses, cell death, the inflammasome and ER and oxidative stresses provide new insights into such stimuli. Understanding the regulation of and interaction between profibrotic cytokines such as TGFb, IL-13, and CTGF are shedding additional light on fibrotic processes. Recent studies indicate that fibrosis is mediated by dedicated progenitor and resident cells within target tissues. Fibroblast and perivascular cell phenotype and differentiation are regulated not only by cytokines, but also by matrix composition and stiffness. Advances in the treatment of idiopathic pulmonary fibrosis and systemic sclerosis herald many new anti-fibrotic therapies that will soon enter clinical trials. Thus, mechanistic understandings will soon answer the long-standing clinical challenges of fibrotic and end-stage scarring diseases. This meeting aims to: 1) Present and discuss the most current and cutting-edge results regarding the mechanisms, signaling pathways, gene regulation, cells and tissues involved in fibrotic diseases and therapeutic approaches currently in development; 2) Include discussions and presentation of new ideas or paradigms that challenge existing models and expand on the knowledge of the current standard of care for fibrotic diseases; 3) Consider the future directions of the field, including the identification of the most pressing unanswered questions, the areas needing more focus, and those that would benefit from new approaches and methodologies developed and used in other related fields; 4) Stimulate collaborations in a setting conducive to focused, intense discussion among scientists with broad interests in fibrotic diseases and different targeted therapeutic approaches, including engagement with industrial partners interested in new targets in fibrotic disease; and 5) Provide a forum for trainees and new investigators to learn about current work in the field, to present their own work and to network with established investigators.